Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Luye Pharma Group Ltd.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05321602CT.gov Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder | — | Completed | — | — | — |
NCT04922593CT.gov Relative Bioavailability of LY03010 Compared to Listed Drug | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mood Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ly03010 (this asset) | Luye Pharma Group Ltd. | P1 | CCC · 52 |
| Brexpiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | P3 | BBB |
| Olanzapine | University of Ghana Medical School | P4 | BBB |
| Minocycline | Pakistan Institute of Living and Learning | P4 | BBB |
| Fluoxetine | University of Ghana Medical School | P4 | BBB |
| Paliperidone | Luye Pharma Group Ltd. | P3 | BB |
| Quetiapine | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Amitryptaline | University of Ghana Medical School | P4 | BB |
| Risperidone | University of Ghana Medical School | P4 | BB |
+25 more in the Mood Disorder cohort
Other indications for ly03010
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mental Disorder | — | P1 | CCC · 50 |
| Schizophrenia | — | P1 | CCC · 48 |
| Psychotic Disorder | — | P1 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ly03010 in Mood Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ly03010-mood-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →